TVA Medical is developing a minimally invasive therapy for end-state renal disease, everlinQ, endoAVF System, and to progress that effort, they have now brought in $15 million with investor financing.
The Series C investing comes with the financial input from Baxter Ventures and Boston Scientific Corporation, primarily. Existing investors include Santé Ventures, S3 Ventures, TriStar Technology Ventures and other strategic investors, according to a statement.
As the statement described: The everlinQ, endoAVF System is a catheter-based technology designed to create hemodialysis access for chronic kidney disease patients. Funds will support the ongoing Novel Endovascular Access Trial (NEAT) clinical study (12-month follow up to complete in 2016) and additional global clinical research, as well as device reimbursement and market access initiatives.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
“We are committed to providing kidney failure patients and caregivers with a minimally invasive endovascular arteriovenous (AV) fistula option,” said Adam L. Berman, president & chief executive officer of TVA Medical. “This financing strengthens our ability to bring the innovative everlinQ endoAVF System to the global market.”